Drug Discovery

Charles River Laboratories, Curigin partner on gene therapy

Charles River Laboratories International has teamed up with Korean biotechnology company Curigin for producing oncolytic ribonucleic acid interference (RNAi) gene therapy.

EdgeCap Partners buys majority stake in Comac Medical

Private equity and growth capital firm EdgeCap Partners has acquired a majority stake in Bulgarian clinical research solutions organisation (CRO) Comac Medical.

Athenex files proceedings under Chapter 11 of US Bankruptcy Code

Biopharmaceutical company Athenex and some of its subsidiaries voluntarily have filed Chapter 11 proceedings of the US Bankruptcy Code.

SGS picks 60% stake in Nutrasource

Swiss company SGS has purchased a majority stake in Nutrasource Pharmaceutical and Nutraceutical Services as well as its subsidiaries (Nutrasource).

Sandoz, Just – Evotec Biologics tie up to develop multiple biosimilars

Sandoz and Evotec’s Seattle-based subsidiary, Just - Evotec Biologics have reached a multi-year, long-term tech alliance to develop and manufacture multiple biosimilars.

Life Bio, Forge to develop gene therapies for aging-linked diseases

Life Biosciences has announced a cGMP manufacturing collaboration with Forge Biologics for advancing the development of new gene therapies to treat aging-related diseases.

Neogap, Cellerys partner for study of multiple sclerosis therapy

Biopharmaceutical company Neogap Therapeutics has partnered with Swiss company Cellerys for a Phase II study of the latter’s RED4MS therapy for multiple sclerosis.

Hansa Biopharma enters into collaboration with Genethon

Swedish biotech company Hansa Biopharma has entered a research and development collaboration with Genethon.

Stablix, Vertex partner to develop targeted protein stabilisation therapies

Biopharmaceutical company Stablix and Vertex Pharmaceuticals have joined forces to discover and develop targeted protein stabilisation (TPS) therapies.